4896 fundamentals

K Pharma, Inc. engages in the research, development, manufacture, and sales of pharmaceuticals and regenerative medicine products. It also offers induced pluripotent stem (IPS) cells, which can also be cultured directly from patient samples to reproduce diseased cells for use in researching pathological mechanisms and developing drug treatments. The company was founded by Komei Fukushima, Hideyuki Okano and Masaya Nakamura on November 1, 2016 and is headquartered in Tokyo, Japan.